Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001–2006

Background  Several new therapeutic options for psoriasis have been tested in clinical trials in recent years. Choice of comparator, study duration and outcome measures are critical for interpreting application of trial results to clinical practice.

[1]  A. Naik,et al.  The neglected purpose of comparative-effectiveness research. , 2009, The New England journal of medicine.

[2]  S. Tunis,et al.  Does comparative-effectiveness research threaten personalized medicine? , 2009, The New England journal of medicine.

[3]  K. Volpp,et al.  Comparative effectiveness--thinking beyond medication A versus medication B. , 2009, The New England journal of medicine.

[4]  J. Avorn.  Debate about funding comparative-effectiveness research. , 2009, The New England journal of medicine.

[5]  Philip W. Lavori,et al.  New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. , 2009, The New England journal of medicine.

[6]  J. Iglehart,et al.  Prioritizing comparative-effectiveness research--IOM recommendations. , 2009, The New England journal of medicine.

[7]  T. Pincus,et al.  Rheumatoid arthritis: strategy more important than agent , 2009, The Lancet.

[8]  H. Williams,et al.  Adalimumab vs methotrexate for the treatment of chronic plaque psoriasis. , 2009, Archives of dermatology.

[9]  L. Naldi,et al.  Psoriasis (chronic plaque). , 2009, BMJ clinical evidence.

[10]  M. Lebwohl,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) , 2008, The Lancet.

[11]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[12]  Consuelo Huerta,et al.  Incidence and risk factors for psoriasis in the general population. , 2007, Archives of dermatology.

[13]  J. Saurat,et al.  Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) , 2007, The British journal of dermatology.

[14]  Hyon K. Choi,et al.  Smoking and the risk of psoriasis in women: Nurses' Health Study II. , 2007, The American journal of medicine.

[15]  J. Grob.  Why are quality of life instruments not recognized as reference measures in therapeutic trials of chronic skin disorders? , 2007, The Journal of investigative dermatology.

[16]  Hyon K. Choi,et al.  Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. , 2007, Archives of internal medicine.

[17]  C. Griffiths,et al.  Pathogenesis and clinical features of psoriasis , 2007, The Lancet.

[18]  R. Stern,et al.  Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective. , 2007, Archives of dermatology.

[19]  H. Jacobe,et al.  Understanding clinical trial outcomes: design, analysis, and interpretation , 2007, Dermatologic therapy.

[20]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[21]  D. Margolis,et al.  Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study. , 2006, Journal of the American Academy of Dermatology.

[22]  K. Lohr,et al.  A simple and valid tool distinguished efficacy from effectiveness studies. , 2006, Journal of clinical epidemiology.

[23]  Alastair J J Wood,et al.  A proposal for radical changes in the drug-approval process. , 2006, The New England journal of medicine.

[24]  P. Rothwell,et al.  Factors That Can Affect the External Validity of Randomised Controlled Trials , 2006, PLoS clinical trials.

[25]  K. Katz.  ‘Biologics’: a clinically meaningless term , 2006, The British journal of dermatology.

[26]  David Moher,et al.  Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary. , 2005, Journal of clinical epidemiology.

[27]  I. Chalmers,et al.  Is the NHS willing to help clinicians and patients reduce uncertainties about the effects of treatments? , 2005, Clinical medicine.

[28]  R. Horton,et al.  Independent clinical research in Europe , 2004, The Lancet.

[29]  L. Naldi,et al.  Epidemiology of psoriasis. , 2004, Current drug targets. Inflammation and allergy.

[30]  H. Williams,et al.  Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. , 2003, The Journal of investigative dermatology.

[31]  L. Vaillant,et al.  The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo‐controlled randomized trial , 2003, The British journal of dermatology.

[32]  R. Kaufmann,et al.  Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis , 2002, Dermatology.

[33]  J. Wright.  Evaluating the outcome of treatment. Shouldn't We be asking patients if they are better? , 2000, Journal of clinical epidemiology.

[34]  R. Stern,et al.  The outcomes movement and new measures of the severity of psoriasis. , 1996, Journal of the American Academy of Dermatology.

[35]  J C Bailar,et al.  Crossover and self-controlled designs in clinical research. , 1984, The New England journal of medicine.

[36]  P. Lavori,et al.  Designs for experiments--parallel comparisons of treatment. , 1983, The New England journal of medicine.

[37]  Frederick Mosteller,et al.  Reporting on methods in clinical trials. , 1982, The New England journal of medicine.

[38]  T C Chalmers,et al.  A method for assessing the quality of a randomized control trial. , 1981, Controlled clinical trials.

[39]  H. P. S. Teglbéerg,et al.  PATHOGENESIS AND THERAPY , 1954, Acta psychiatrica et neurologica Scandinavica.

[40]  B. Strober,et al.  Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. , 2008, Journal of the American Academy of Dermatology.

[41]  A. Gottlieb,et al.  A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. , 2007, Journal of the American Academy of Dermatology.

[42]  A. Gottlieb.  Psoriasis: emerging therapeutic strategies , 2005, Nature Reviews Drug Discovery.

[43]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS INDICATED FOR THE TREATMENT OF PSORIASIS , 2004 .

[44]  Douglas G. Altman,et al.  Systematic Reviews in Health Care , 2001 .

[45]  H. P. Teglbjaerg.  Pathogenesis and therapy. , 1954, Acta psychiatrica et neurologica Scandinavica.